Exercise and asthma: β2-agonists and the competitive athlete

Breathe

Volumn 7, Issue 1, 2010, Pages 65-71

  Boulet, L P ^a   Hancox, R J ^b,c   Fitch, K D ^d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c WAIKATO HOSPITAL   (New Zealand)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650335344     PISSN: 18106838     EISSN: 20734735     Source Type: Journal    
DOI: 10.1183/18106838.0701.064     Document Type: Article

References (33)

1. Fitch KD, Sue-Chu M, Anderson SD, et al. Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. J Allergy Clin Immunol 2008; 122: 254-260.
2. Anderson, SD, Kippelen, P. Exercise-induced bronchoconstriction: pathogenesis. Curr Allergy Asthma Rep 2005; 5: 116-122.
3. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. Am J Respir Crit Care Med 2009; 180: 59-99.
4. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2009, www.ginasthma.com.
5. Subbarao P, Duong M, Adelroth E, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol 2006; 117: 1008-1013.
6. Lougheed MD, Lemiere C, Dell S, et al. Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children 6 years and over and Adults. Can Respir J 2010; 17: 15-30.
7. McKenzie DC, Boulet LP. Asthma, outdoor air quality and the Olympic Games. CMAJ 2008; 179: 543-548.
8. Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 2006; 368: 794-803.
9. Polosa R. Critical appraisal of antileukotriene use in asthma management. Curr Opin Pulm Med 2007; 13: 24-30.
10. Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med 2005; 35: 565-574.
11. Sue-Chu M, Karjalainen EM, Laitinen A, et al. Placebo-controlled study of inhaled budesonide on indices of airway inflammation in bronchoalveolar lavage fluid and bronchial biopsies in cross-country skiers. Respiration 2000; 67: 417-425
12. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guidelines on the management of asthma: A national clinical guideline; 2008 May (revised 2009).
13. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, National Institutes for Health, 2007.
14. Gibson GJ, Greenacre JK, König P, et al. Use of exercise challenge to investigate possible tolerance to beta-adrenoceptor stimulation in asthma. Br J Dis Chest 1978; 72: 199-206.
15. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363-368.
16. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996; 153: 65-69.
17. Simons FER, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997; 99: 655-659.
18. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141-146.
19. Garcia R, Guerra P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Invest Allergol Clin Immunol 2001; 11: 176-182
20. Hancox RJ, Subbarao P, Kamada D, et al. Beta2-agonist tolerance and exercise-induced bronchospasm. Am J Respir Crit Care Med 2002; 165: 1068-1070.
21. Kersten ETG, Driessen JMM, van Leeuwen JC, et al. Pilot study: The effect of reducing treatment on exercise induced bronchoconstriction. Pediatric Pulmonology 2010; [Epub ahead of print 001:10.1002/ppul.21278].
22. Storms W, Chervinsky P, Ghannam AF, et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 2004; 98: 1051-1062.
23. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta agonists during acute bronchoconstriction. Eur Respir J 1999; 12: 283-287.
24. Haney S, Hancox RJ. Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials. Respir Res 2007; 8: 19.
25. Wraight JN, Hancox RJ, Herbison GP, et al. Bronchodilator tolerance: the impact of increasing bronchoconstriction. Eur Respir J 2003; 21: 810-815.
26. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clin Rev Allergy Immunol 2006; 31: 181-196.
27. Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005; 99: 566-571.
28. Aziz I, Tan KS, Hall IP, et al. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 1998; 12: 580-584.
29. Davis BE, Reid JK, Cockcroft DW. Formoterol thrice weekly does not result in the development of tolerance to bronchoprotection. Can Respir J 2003; 10: 23-26.
30. Fitch KD. β-agonists at the Olympic Games. Clin Rev Allergy Immunol 2006; 31: 259-268.
31. Anderson SD, Fitch KD, Perry CP, et al. Reponses to bronchial challenges submitted for approval to use an inhaled beta 2 agonist prior to an event at the 2002 Winter Olympics. J Allergy Clin Immunol 2003; 111: 45-50.
32. Anderson, SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a β-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol 2006; 117: 767-773.
33. www.wada-ama.org/en/Science-Medicine/Prohibited-List/ Accessed 28 March 2010.